But, diagnostic yield of advanced neoplasia among participants higher with colonoscopy
TUESDAY, Nov. 15 (HealthDay News) -- Participation rates for colorectal cancer (CRC) screening are significantly higher with computed-tomography (CT) colonography, but the diagnostic yield for advanced neoplasia among participants is higher in those who undergo colonoscopy, according to a study published online Nov. 15 in The Lancet Oncology.
Esther M. Stoop, M.D., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues compared participation and diagnostic yields for CRC screening with colonoscopy versus non-cathartic CT colonography. Individuals aged 50 to 75 years were invited for colonoscopy (5,924 invitees) or CT colonography (2,920 invitees). The participation rate (number of invitees who underwent screening relative to the total number of invitees), and diagnostic yield (the number of participants with advanced neoplasia relative to total number of invitees) were assessed.
The investigators found that participation rates were significantly higher for CT colonography than colonoscopy (34 versus 22 percent). The diagnostic yield for all advanced neoplasia per 100 participants was significantly higher for colonoscopy versus CT colonography (8.7 versus 6.1 per 100 participants). The diagnostic yield for all advanced neoplasia per 100 invitees was similar for colonoscopy and CT colonography (1.9 versus 2.1; P = 0.56). The diagnostic yield for advanced neoplasia (≥10 mm) per 100 invitees was 1.5 for colonoscopy versus 2.0 for CT colonography.
"The participation rate was higher with CT colonography than with colonoscopy, whereas colonoscopy identified more advanced neoplasia in participants than did CT colonography," the authors write.
Supplies for the study were provided by Guerbet, Philips Healthcare, and Norgine.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)